Kim Ji-Hyun, Kim Shinn-Young, Shin Eun-Young, Jung Ji-Han, Choi Hyun-Joo, Jun Kyong-Hwa
Department of Surgery, Seoul St. Mary's Hospital, Seocho-gu, Seoul 06591, Republic of Korea.
Department of Surgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Gyeonggi-do 16247, Republic of Korea.
Oncol Lett. 2019 Sep;18(3):2661-2669. doi: 10.3892/ol.2019.10594. Epub 2019 Jul 9.
The aim of the present study was to evaluate programmed death-1 (PD-1) and programmed death-1 ligand-1 (PD-L1) expression in gastric carcinoma and to assess their effect on survival rate. A total of 170 surgically resected specimens were obtained from patients diagnosed with gastric carcinoma at St. Vincents Hospital, The Catholic University of Korea. Paraffin tissue sections from tissue microarray blocks were subjected to immunohistochemical analysis of PD-1 and PD-L1. In addition, PD-1 expression on CD4 and CD8 T cells isolated from peripheral blood mononuclear cells and gastric cancer tissues was evaluated by multicolor flow cytometry. PD-1 and PD-L1 were expressed in 30.0 and 60.5% of the gastric cancer tissues, respectively. The expression of PD-L1 was higher in patients with advanced T (P=0.035) and Tumor, Node and Metastasis stage (P=0.05). The patients with positive PD-L1 expression had shorter disease-free survival time than those without PD-L1 expression (P=0.005). Additionally, PD-L1 expression was significantly associated with poor prognosis (P=0.015). PD-1 and PD-L1 expression levels were significantly higher on CD8 T cells than on CD4 T cells (P<0.001). The data of the present study suggested that PD-L1 expression may be an independent indicator of poor prognosis in patients with gastric cancer. Furthermore, PD-L1 expression may play a role in immune evasion of gastric cancer.
本研究的目的是评估程序性死亡受体 1(PD-1)和程序性死亡受体 1 配体 1(PD-L1)在胃癌中的表达,并评估它们对生存率的影响。总共从韩国天主教大学圣文森特医院被诊断为胃癌的患者中获取了 170 份手术切除标本。对组织芯片蜡块的石蜡组织切片进行 PD-1 和 PD-L1 的免疫组织化学分析。此外,通过多色流式细胞术评估从外周血单个核细胞和胃癌组织中分离出的 CD4 和 CD8 T 细胞上的 PD-1 表达。PD-1 和 PD-L1 分别在 30.0%和 60.5%的胃癌组织中表达。PD-L1 的表达在 T 分期较晚(P = 0.035)和肿瘤-淋巴结-转移(TNM)分期(P = 0.05)的患者中更高。PD-L1 表达阳性的患者无病生存期比 PD-L1 表达阴性的患者短(P = 0.005)。此外,PD-L1 表达与预后不良显著相关(P = 0.015)。CD8 T 细胞上的 PD-1 和 PD-L1 表达水平显著高于 CD4 T 细胞(P < 0.001)。本研究数据表明,PD-L1 表达可能是胃癌患者预后不良的独立指标。此外,PD-L1 表达可能在胃癌的免疫逃逸中起作用。